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Background: Mild cognitive impairment (MCI) is a clinical stage indicating a prodromal
phase of dementia. This practical concept could be used also for fronto-temporal
dementia (FTD). Progranulin (PGRN) has been recently recognized as a useful diagnostic
biomarker for fronto-temporal lobe degeneration (FTLD) due to GRN null mutations.
Electroencephalography (EEG) is a reliable tool in detecting brain networks changes. The
working hypothesis of the present study is that EEG oscillations could detect different
modifications among FTLD stages (FTD-MCI versus overt FTD) as well as differences
between GRN mutation carriers versus non-carriers in patients with overt FTD.
Materials and Methods: EEG in all patients and PGRN dosage in patients with a clear
FTD were detected. The cognitive state has been investigated through mini mental state
examination (MMSE).
Results: MCI-FTD showed a significant lower spectral power in both alpha and theta
oscillations as compared to overt FTD. GRN mutations carriers affected by FTLD show
an increase in high alpha and decrease in theta oscillations as compared to non-carriers.
Conclusion: EEG frequency rhythms are sensible to different stage of FTD and could
detect changes in brain oscillatory activity affected by GRN mutations.
Keywords: EEG, FTD, PGRN positive, PGRN negative, MCI FTD
INTRODUCTION
Fronto-temporal lobar degeneration (FTLD) is a neurodegenerative disorder characterized by
behavioral abnormalities, language impairment, and deficits in executive functions as the most
typical clinical features (Seelaar et al., 2011). FTLD is clinically heterogeneous, as different clinical
variants have been carefully described. On the basis of presenting clinical symptoms, behavioural
variant FTD (bvFTD), agrammatic variant of Primary Progressive Aphasia (avPPA), and semantic
variant of PPA (svPPA) represent the most common phenotypes (Benussi et al., 2015). Each
one presents specific neuroimaging hallmarks; bvFTD is characterized by mesial and dorsolateral
frontal damage, prevalent on the right side, avPPA is defined by involvement of Broca’s area and
left insula, whilst svPPA usually presents left rostral temporal involvement (Lashley et al., 2015).
Moreover, FTD is chacterized also by early stages, usually named mild cognitive impairment
(MCI), that are still not completely characterized. Unfortunately, the diagnosis of FTD can be
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difficult because of its insidious and gradual onset and can also be
misdiagnosed as Alzheimer’s disease (AD) (Rankin et al., 2005;
Walker et al., 2005).
The discovery of mutations in GRN as a genetic determinant
for FTLD resulted in the rapid identification of a large number
of families carrying GRN mutations, inherited in an autosomal
dominant pattern. At present, 77 different mutations in more
than 240 unrelated families have been described (Ghidoni et al.,
2012a). Mutations in GRN have been associated with a broad
spectrum of clinical phenotypic variability (Benussi et al., 2008;
Rohrer et al., 2010a,b).
GRN null mutations cause protein haploinsufficiency, leading
to a significant decrease in progranulin (PGRN) levels that
can be detected in plasma, serum, and cerebrospinal fluid
of mutation carriers (Ghidoni et al., 2008, 2012b; Finch
et al., 2009; Sleegers et al., 2009). It has been reported that
PGRN promotes neuronal survival and neurite outgrowth in
cultured neurons (Van Damme et al., 2008) and enhances
neuronal survival under stress conditions (Kessenbrock et al.,
2008). Data from GRN knockout experimental models suggest
that PGRN deficiency leads to reduced synaptic connectivity
and impaired plasticity, which may be contributing factors
to FTLD pathology in human patients (Tapia et al., 2011;
Petkau et al., 2012). Brain activity could be widely and
variously affected in FTLD patients with GRN mutations.
Neuroimaging studies have shown that the topography of
brain atrophy is frequently asymmetric, and predominantly
involves the frontal, temporal, and parietal cortex (Whitwell
et al., 2012). Nevertheless, a recent study (Caroppo et al.,
2014) have demonstrated that a diffuse and bilateral white
matter involvement is common in patients with GRN mutations.
The presence of white matter lesions is not surprising since
expression of PGRN, not only in neurons but also in
activated microglia, in astrocytes and oligodendroglia, has been
previously ascertained (Ahmed et al., 2010). As a consequence,
cortical and subcortical loop are both implicated in the
disruption of intrinsic brain networks in GRN mutations
carriers.
Electroencephalography is a reliable and non-invasive tool for
the study of brain networks in dementia. Relationship of the
brain oscillations with intrinsic brain network like default mode
network (DMN) have been extensively studied (Nishida et al.,
2015). In particular, alpha and theta field potentials are deeply
involved in tuning the large and local scale networks interactions
in cognitive and psychiatric illnesses (Koenig et al., 2001; Tenke
et al., 2011). Previous EEG studies have demonstrated peculiar
modifications in brain oscillations in patients with MCI due
to AD as compared to non-AD converters (Moretti et al.,
2011a). Moreover, these changes in brain oscillations have
been correlated with temporo-parietal and hippocampal atrophy
(Moretti et al., 2007a, 2008a, 2009a,b, 2011a, 2012) as well as
to white matter lesions (Moretti et al., 2007b, 2008b). In the
present explorative study, we test the working hypothesis that
changes in EEG oscillations could specifically detect different
stages of FTLD, namely MCI-FTD versus overt FTD, as well as
differences between GRN mutation carriers versus non- carriers.
The search for new biomarkers is of great importance for an
early diagnosis and for monitoring the effectiveness of new
therapies.
MATERIALS AND METHODS
Subjects
Diagnostic Criteria
Clinical diagnosis of FTLD and LBD were made according
to international guidelines (McKeith et al., 1996; Neary et al.,
1998) as well as more recent revised criteria for the diagnosis
of frontotemporal dementia (Gorno-Tempini et al., 2011;
Rascovsky et al., 2011). MCI-FTD patients were recruited
with mini mental state examination (MMSE) score higher
than 24/30. Eleven patients with MCI-FTD, eight FTLD
patients carrying GRN mutations, and 20 FTLD patients
not carrying GRN mutations were included in the present
study (Table 1). The diagnosis of the enrolled subjects is
reported in Table 2. All patients underwent a series of
standardized diagnostic and severity instruments, including:
the MMSE (Folstein et al., 1975), the Clinical Dementia
Rating Scale (CDRS; Hughes et al., 1982), the Hachinski
Ischemic Scale (HIS; Rosen et al., 1980), the Instrumental
and Basic Activities of Daily Living (IADL, BADL; Lawton
and Brody, 1969) and a comprehensive neuropsychological
battery (Lezak et al., 2004). The patients were recruited only
with apparently primary cognitive deficits excluding psychic
comorbid conditions like anxiety, depression, psychosis etc.,
or physical comorbidities like hypothiroidism, uncontrolled
diabetes, vitamin B12, and folate deficiency, uncontrolled heart
disease or hypertension, drug addiction, or alcohol abuse.
Moreover, none of the patients was taking any drugs that
might affect the EEG, namely psychoactive drugs, including
acetylcholinesterase inhibitors or other drugs enhancing brain
cognitive functions. In addition, patients underwent diagnostic
neuroimaging procedures (magnetic resonance imaging, MRI),
and laboratory testing to rule out other causes of cognitive
impairment. In particular, MRI was able to exclude patients with
major cerebrovascular diseases or other diseases (like tumors)
that might influence EEG frequency rhythms. On the whole, 13
patients with primary progressive non-fluent aphasia (PNFA), 12
patients with the behavioral variant of FTD (FTD-bv), one patient
with the semantic variant of FTD (FTD-sv), and one patient
with Lewy Body Disease (LBD) were recruited. Demographic and
clinical features of the sample in study are reported in Table 2.
All experimental protocols had been approved by the local
ethics committee of Scientific Institute for Research and Care
(IRCCS) of Alzheimer’s and psychiatric diseases ‘Fatebenefratelli’
in Brescia, Italy (Protocol numbers: 26/2014; 50/2015). Written
informed consent was obtained from all participants or their
caregivers, according to the Code of Ethics of the World Medical
Association (Declaration of Helsinki).
EEG Recordings
The EEG activity was recorded continuously from 19 sites by
using electrodes set in an elastic cap (Electro-Cap International,
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TABLE 1 | ANOVA results of demographic variable (age, education) MMSE
score, and of PGRN dosage, high alpha, and theta EEG power of the study
sample.
GRN positive GRN negative MCI FTD p
Number of subjects 8 20 11 –
Age, years 65,7 ± 9,3 67,2 ± 9,2 64,8 ± 4,2 0,07
Education, years 7,4 ± 2,8 7,6 ± 4,2 7,6 ± 3,1 0,9
MMSE 21,3 ± 5,6 20,5 ± 4,3 26,2 ± 5,1 0,11
PGRN dosage 33,6 ± 18,5 142,4 ± 72,1 n.a. 0.001
High alpha EEG power 15,2 ± 3,5 10,6 ± 3,2 8,7 ± 2,8 0,003
Theta EEG power 13,8 ± 5,1 21,1 ± 2,1 4,3 ± 8,3 0,002
TABLE 2 | Clinical diagnosis of the patients recuited in the study.
DIAGNOSIS PGRN positive PGRN negative
FTD PPA 4 9
FTDbv 2 10
FTD 1 1
LBD 1
FTD, fronto-temporale dementia; PPA, primary progressive aphasia; bv, behavioral
variant; LBD, Lewy body dementia
Inc. Eaton, OH, USA) and positioned according to the 10–
20 international system (Fp1, Fp2, F7, F3, Fz, F4, F8, T3, C3,
Cz, C4, T4, T5, P3, Pz, P4, T6, O1, and O2). All recordings
were obtained in the morning with subjects resting comfortably.
The patients were instructed to sit with closed eyes and relax
and vigilance was continuously monitored in order to avoid
drowsiness by an operator. The ground electrode was placed in
front of Fz. The left and right mastoids served as the reference
points for all electrodes. The recordings were used off-line to
re-reference the scalp recordings to the common average. Re-
referencing was done prior to the EEG artifact detection and
analysis. Data were recorded with a band-pass filter of 0.3–
70 Hz and digitized at a sampling rate of 250 Hz (BrainAmp,
BrainProducts, Munich, Germany). Electrode-skin impedance
was set below 5 k. Horizontal and vertical eye movements
were detected by electrooculogram (EOG). The recording lasted
5 min with the subjects’ eyes closed. EEG data were then analyzed
and fragmented off-line in consecutive epochs of 2 s with a
frequency resolution of 0.5 Hz. The average number of epochs
analyzed was 140, ranging from 130 to 150. The epochs with
ocular, muscular, and other types of artifacts were discarded
by two skilled electroencephalographists. The spectral power
we obtained is an estimation of a spectrum collapsed all over
the scalp electrodes. In this way, the eventual contribution of
the muscular or other artifacts is strongly reduced. Moreover,
two skilled electroencephalographists checked separately the EEG
traces (Moretti et al., 2003, 2004).
Analysis of Frequency Bands
A digital FFT-based power spectrum analysis (Welch technique,
Hanning windowing function, no phase shift) computed the
power density of EEG rhythms (ranging from 2 to 45 Hz) with
a 0.5 Hz frequency resolution. The frequency bands range was
computed on fixed limit as follows: (1) delta, 1–3 Hz; (2) theta,
4–7 Hz; (3) alpha 1 ore low alpha, 8–10,5 Hz; (4) alpha 2 ore
high alpha, 10.5–14 Hz. These frequencies were computed on
the power spectra averaged across all recording electrodes. This
“collapsed spectrum method,” being a normalized scalp spectrum,
determined a global field power (Moretti et al., 2003, 2004).
Genetic Analysis
GRN gene was analyzed in patients with FTLD and LBD by
direct sequencing of all exonic and flanking intronic regions as
previously described (Benussi et al., 2008). Plasma PGRN levels
were measured in duplicate using an ELISA kit (Human PGRN
ELISA Kit, AdipoGen Inc., Seoul, Korea) as previously reported
(Ghidoni et al., 2012b). GRN positive carriers belongs to different
families. This choice has been made to avoid that EEG patterns
could be due to familial relationships. Tables 2 and 3 shows the
clinical diagnosis and related genetic mutations of GRN positive
carriers.
Statistical Analysis
One-way analysis of variance (ANOVA) has been performed to
compute the differences between groups (independent variables)
in sociodemographic, MMSE score, PGRN dosage, and EEG
oscillations (dependent variables) and neuropsychological tests.
Age, education, and MMSE score have been used as covariates in
ANOVA of brain rhythms to avoid confounding factors.
RESULTS
Table 1 shows ANOVA significant results. As expected, the
PGRN dosage was significantly different, with an impressive
decrease in GRN null mutation carrier patients [F(19,77),
df = 1, p < 0.001], confirming previous results (Ghidoni
et al., 2012b). As about the EEG rhythms, results show: 1)
a significant increase of high alpha power in GRN positive
mutations carriers [F(4,22), df = 2, p = 0.003]; (2) a significant
increase of theta power in GRN negative patients [F(3,14), df = 2,
p= 0.002).
ANOVA analysis showed a decrease of the theta and alpha
spectral power in MCI-FTD as compared to both PGRN positive
TABLE 3 | Genetic mutations identified in the GRN mutations carriers
group and related clinical diagnosis.
PGRN identified mutations Diagnosis
1 PGRN Leu271LeufsX10 FTDsv
2 PGRN Leu271LeufsX10 (g.1977_1980delCACT) FTD-PPA
3 PGRN Leu271LeufsX10 FTD-PPA
4 PGRN Leu271LeufsX10 FTD-PPA
5 PGRN Thr276SerfsX7 FTD-PPA
6 PGRN Leu271LeufsX10 FTDbv
7 PGRN Leu271LeufsX10 FTDbv
8 PGRN Leu 271LeufsX10 LBD
FTDsv, fronto-temporal dementia semantic variant; FTDbv, fronto-temporal
dementia behavioral variant; FTD-PPA, fronto-temporal dementia primary
progressive aphasia; LBD, Lewy, body disease.
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and negative FTD patients. Given that the difference between
PGRN positive and negative FTD patients were limited to
theta and alpha power spectra, other frequency bands were not
considered in the analysis.
The only significant results about neuropsychological battery
were obtained in Token test, fluency for letters and working
memory test. The results showed a general better performance
in MCI-FTD patients as compared to both negative and positive
PGRN mutations carriers (p < 0.01). No significant differences
resulted between the comparison between negative and positive
mutations PGRN carriers.
DISCUSSION
Our results show that FTLD patients carrying GRN mutations
have different changes of EEG rhythms when compared
to patients negative for GRN mutations. Specifically, GRN
mutations carriers demonstrate an increment of the high alpha
and a decreased of the theta power spectra. In this view, the
presence of PGRN, which is a trophic factor for the nervous
system, would allow a reorganization of the neural networks in a
compensatory or adaptive way: accordingly, it has been reported
that PGRN promotes neuronal survival and neurite outgrowth
in cultured neurons (Van Damme et al., 2008) Likewise, under
stress conditions it has been exhibited that PGRN improves
neuronal survival (Kessenbrock et al., 2008). Data from GRN
knockout experimental models suggest that PGRN deficiency
leads to reduced synaptic connectivity and impaired plasticity,
which may be contributing factors to FTLD pathology in human
patients (Tapia et al., 2011; Xu et al., 2011). On the other
hand, the white matter impairment in GRN mutation carriers
has been directly proved in a recent study (Caroppo et al.,
2014). In this study, four patients carrying GRN mutation were
investigated and in all of them mostly confluent white matter
lesions, affecting the periventricular subcortical white matter and
U-fibers, were found mainly in the frontal and parietal lobes.
This trophic activity could be shown by the maintenance of
theta brain oscillations. Of note, fronto-parietal network are
well recognized potential generators of theta oscillations (Beck
et al., 2008; Ghetti et al., 2008; Whitwell et al., 2009), traveling
on long pathway bundles of the white matter of fronto-parietal
lobes and related subcortical structures like brainstem, and
corpus callosum systems (Rohrer et al., 2010a,b). In particular, a
recent study investigating the cortical generators of theta brain
rhythm, through intracranial electrode recordings, have found
that the higher percentage of cortical gated theta oscillations
is situated in parieto-occipital regions (Raghavachari et al.,
2006). So, a possible explanation of the spared maintenance
of theta power in FTLD patients negative for GRN mutations
as compared to GRN mutations carriers could be related to
the relative integrity of parieto-occipital areas, embedded in the
DMN.
Not surprisingly, in case of PGRN deficiency, the high alpha
frequency spectral power increments. The alpha oscillation is the
rhythm that mirrors the brain electrical signal of the parietal-
occipital default system, profoundly connoted with higher
cognitive abilities (Klimesch, 2012; Moretti, 2015a). Recent
studies have shown that mutations in GRN are correlated with
atrophy of the parietal lobes (Pickering-Brown et al., 2008;
Seeley, 2008; Van Swieten and Heutink, 2008). In particular,
a recent study investigating brain network connectivity with
functional resting state MRI (Premi et al., 2014) utilizing
three measures of both local and global connectivity (the
regional homogeneity, the fractional amplitude of low frequency
fluctuation and the degree centrality) has shown that parietal
lobes are affected very early in GRN mutation carriers, so
that the notion of fronto-parietal dementia for PGRN related
disease should be considered. The parietal lobes are well-
recognized core regions of the DMN (Sala-Llonch et al., 2015).
Previous studies have demonstrated that high alpha rhythm
synchronization (or increase) is a marker of loss of function
in the default system, as exhibited in patients with prodromal
or overt AD (Moretti et al., 2011b, 2013a,b, 2014a,b; Moretti,
2015b,c,d). The increase of high alpha oscillation in FTD patients,
characterized by the loss of PGRN, confirms the reliability of
this biomarker as a sign of DMN impairment. Moreover, the
lack of PGRN is confirmed to be connected to the disruptive of
the default system, determining real reverberations on cognitive
capacity.
As expected, MCI-FTD have better cognitive performance,
especially in frontal function assessment tests, as compare to
overt FTD patients both carriers and non-carriers of GRN
mutation. Moreover, in MCI-FTD the lower spectral power
of theta and alpha power could be explained with an initial
stage of the disease in which EEG changes are not still clear.
A possible fingerprint of this stage could be the ratio between
alpha and theta power spectra. The progression of disease could
modify the EEG oscillations, as observed in overt FTD and
more strongly in GRN mutation positive patients. Anyway, future
studies will clarify if the presence or absence of PGRN mutations
also in MCI-FTD could unveil more peculiar brain oscillations
changes.
Study Limitations
It should be remarked a main limitation of the study that is
the small sample size. We want to highlight that it should be
considered the exploratory nature of the study. In this view, the
choice criteria and statistical outcomes are sufficiently robust to
be confident in the overall reliability of the results. In particular,
the straight difference between MCI-FTD and overt FTD patients
confirm that results are not due to mere random chance
results. Despite this limitation, it provides important results for
future studies. Up to date, for the first time in this paper, the
particular aspect of a neurophysiological EEG biomarker in GRN
mutation carriers and non-carriers have been investigated. Most
important, the detection of a neuropshysiological biomarker,
related to functional, and structural changes, could open new
windows on integrated research strategy about the molecular
nexopathies shedding light on the way through which different
proteinopathies could differently affect neural networks (Warren
et al., 2013). Finally, the finding of a new biomarker could be
helpful for early diagnosis, to monitor the progression of disease
and to test disease-modifying drugs. Anyway, we are well aware
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of the need to correlate the results with a wider morphological
and neuropathological characterization as well as with other risk
factors.
CONCLUSION
GRN mutations affect brain oscillatory activity. A better
understanding of the complexity of PGRN biology in the brain
will help guide the development of PGRN-modulating therapies
for neurodegenerative disease. Further studies with a larger
number of subjects are needed to confirm the present results.
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